Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary report.
Saved in:
| Title: | Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary report. |
|---|---|
| Authors: | Kawamura, Yusuke1,2 (AUTHOR) k-yusuke@toranomon.gr.jp, Akuta, Norio1,2 (AUTHOR), Shindoh, Junichi2,3 (AUTHOR), Matsumura, Masaru2,3 (AUTHOR), Okubo, Satoshi2,3 (AUTHOR), Tominaga, Licht2,4 (AUTHOR), Yamamoto, Shigeki1,2 (AUTHOR), Eriksson, Yasuka1,2 (AUTHOR), Hosaka, Tetsuya1,2 (AUTHOR), Saitoh, Satoshi1,2 (AUTHOR), Sezaki, Hitomi1,2 (AUTHOR), Suzuki, Fumitaka1,2 (AUTHOR), Suzuki, Yoshiyuki1,2 (AUTHOR), Ikeda, Kenji1,2 (AUTHOR), Arase, Yasuji1,2 (AUTHOR), Hashimoto, Masaji2,3 (AUTHOR), Kozuka, Takuyo2,4 (AUTHOR), Kumada, Hiromitsu1,2 (AUTHOR) |
| Source: | Hepatology Research. Jun2025, Vol. 55 Issue 6, p948-955. 8p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 13866346 |
|---|---|
| DOI: | 10.1111/hepr.14188 |
